Guiling Medical Secures Tens of Millions in Series A+ Funding to Accelerate Leadership in Advanced Wound Management

Recently, Hangzhou R&L Medical Device Co., Ltd. (hereinafter referred to as “R&L Medical”) successfully completed its A+ round of financing, raising tens of millions of yuan. This round was exclusively invested by Lanwan Sci-Tech Innovation Group. The funds raised will be used for the R&D and regulatory registration of R&L Medical’s product pipeline, scaled-up production, and commercialization, accelerating its leadership in the advanced wound care sector.

Founded in Hangzhou, Zhejiang, in late 2017, R&L Medical is a leading healthcare enterprise dedicated to providing comprehensive solutions for the radical cure of diabetic foot, starting from wound care. The company initially positioned itself in the vast blue ocean market of advanced wound management, leveraging its proprietary technologies and years of deep expertise to deliver a full suite of innovative solutions for infected and hard-to-heal wounds, ranging from precise debridement to prognostic management. Currently, R&L Medical has established three distinct product pipelines focused on precision surgery, advanced nursing, and healthy living, which collectively encompass offerings such as the Mach Knife^®, bone regeneration, total allograft, panoramic view^®, Quan Yu^®more than ten products to meet the needs of patients at all stages of wound management.

Among these, the SECCS Bone Regeneration System is a Class III medical device developed under a major project of the Shanghai Municipal Science and Technology Commission, led by Academician Dai Kerong of Shanghai Ninth People’s Hospital affiliated with Shanghai Jiao Tong University School of Medicine. It enables rapid aspiration and enrichment of bone marrow mesenchymal stem cells within just 7 minutes during surgery to prepare bioactive bone, significantly enhancing bone regeneration capacity. This allows bone repair rates to approach those of autologous bone grafts while eliminating the risk of allogeneic immune rejection. The system is applicable to all clinical procedures requiring bone grafting, and its unique innovative features help more patients achieve clinical benefits, positioning it as a promising future direction for bone repair technologies. This technology seamlessly integrates with the company’s precision surgical product line, including the Mache Knife.^®precision debridement technology and local infection control technology with total bone reduction will provide innovative holistic solutions for orthopedic patients and doctors.

R&L Medical currently operates an R&D and production base spanning over 5,000 square meters, featuring a Class 100,000 GMP workshop, as well as Class 10,000 cleanroom-equipped sterile and microbiology laboratories. The company has passed assessments by the drug regulatory authority and obtained ISO 13485 quality management system certification. Its core R&D team comprises high-caliber domestic and international talents, including senior researchers, technical elites, and industry experts, who possess mastery of core technologies in the medical field.

Currently, R&L Medical has been recognized as a “Hangzhou Municipal High-Tech R&D Center” and listed as a Hangzhou “Fledgling Eagle Plan” enterprise. It won the championship in the special semi-finals of the 8th “Maker China” Competition (Hangzhou Division), was featured as an exhibitor at the National Mass Entrepreneurship and Innovation Week, and is a key recommended enterprise of the Haichuang Park in Hangzhou Future Sci-Tech City, a national-level incubator. The company has secured recognition and investment from multiple rounds of renowned institutions. Over the past three years, R&L Medical’s business has continued to double. In the next two years, several core products strategically prioritized by the company are expected to receive regulatory approval and launch on the market, which will undoubtedly drive faster overall business growth. Meanwhile, the company will establish a new production base to better support business expansion, further realize its vision of leading medical technology innovation, and fulfill its corporate mission of benefiting society and contributing to national prosperity.

Regarding this round of financing, Leo, Founder of R&L Medical, stated: “Guided by our original aspiration to strengthen the nation through industry, R&L Medical has been dedicated to the field of wound care for many years. The company has progressively transitioned from product pipeline development and regulatory approval to genuine industrial-scale production and comprehensive portfolio commercialization. We are deeply grateful to Lanwan Sci-Tech Innovation for its support and assistance at this critical juncture in our development. Through our collaboration with Lanwan Sci-Tech Innovation, we have profoundly recognized our shared commitment to a manufacturing-first philosophy and a diligent, pragmatic work ethic. With the participation of Lanwan Sci-Tech Innovation in this funding round, R&L Medical will fully commence the construction of a new production base to ensure that our product lines can continuously expand their market coverage and penetration. Meanwhile, we will further increase R&D investment, continuously improve production processes, and strive to reduce costs while enhancing efficiency, all in pursuit of realizing our vision of strengthening the nation through industry.”

Deng Jianxin, Founder of Lanwan Sci-Tech Innovation Group, stated: “R&L Medical has built a robust product pipeline centered on perioperative care with a focus on wound management. Several of its innovative products have achieved a leading position in China, possessing unique core market competitiveness and holding strong potential for genuine import substitution. Furthermore, R&L Medical boasts a professional, cohesive team with strong innovation capabilities and comprehensive commercialization expertise. We are honored to establish this strategic partnership with R&L Medical and look forward to seeing the company remain dedicated to innovation and sustained growth, ultimately becoming a benchmark Chinese enterprise in the field of high-end wound management.”

Lanwan Sci-Tech Innovation Group is an innovative industrial ecosystem operator with a strategic focus on the life and health industry. Adopting “industry + platform + capital + operations” as its core business model, the company centers on industrial investment, supported by industrial operations and industrial services, and is committed to building a regional innovation and entrepreneurship ecosystem aligned with Lanwan’s industrial standards.

Lanwan Sci-Tech Innovation currently manages five industrial funds with a total scale exceeding RMB 1.5 billion, focusing on early-stage investments, particularly in angel rounds. It has cumulatively invested in approximately 50 high-tech life and health projects, including Auscan Biopharmaceuticals, Jingze Biology, Yiyang Technology, Haitai Biology, Nuolaisheng Technology, Huyun New Drugs, Nuotan Pharmaceutical, Huiwei Medical, Tanyin Medicine, Tongxuan Medical, Yike Polymers, Hanhe Medical, and Daishengsi Medical.

Meanwhile, Lanwan Sci-Tech Innovation is deeply engaged in the comprehensive development and operation of regional districts. Adhering to the philosophy that “industry is the foundation, talent is the basis, ecology is the soul, platforms are the instruments, capital is the core, and operations are paramount,” it has assisted governments in establishing distinctive industrial clusters such as the Haimen Biopharmaceutical Town, Xianju Medical Device Town, Hanzhong Nuclear Medicine Industrial Park, and Dongying Animal Health and Biopharmaceutical Industrial Park, striving to become the premier accelerator in China’s biomedical sector.